The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)
about
In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell linesRegular use of aspirin and pancreatic cancer risk.Regular aspirin use and lung cancer risk.Tetrandrine and thapsigargin release arachidonic acid from cells in culture and stimulate prostacyclin production in rat liver cells, but may do so by different pathways.Chemoprevention studies within lung cancer screening programmesThe nuclear receptor PPARĪ³ individually responds to serotonin- and fatty acid-metabolitesThe evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimismIncreased NF-kappaB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cellsSuppressive effect of aspirin on aberrant crypt foci in patients with colorectal cancerSulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell linesInhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cellsCOX-2 and cancer: a new approach to an old problemReduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control studyCyclooxygenase-2 and the inflammogenesis of breast cancer.Prostaglandin endoperoxide H synthase expression in human thyroid epithelial cells.Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study.New insights into the molecular pathogenesis of colorectal cancer.Ibuprofen and fatal lung cancer: A brief report of the prospective results from the Third National Health and Nutrition Examination Survey (NHANES III).Use of acetaminophen and risk of endometrial cancer: evidence from observational studies.Reciprocal interactions between human T-lymphotropic virus type 1 and prostaglandins: implications for viral transmission.Non-steroidal anti-inflammatory drug (NSAID) use and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study.Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effectMethylation and colorectal cancer.Effect of COX-2 inhibitors and other non-steroidal inflammatory drugs on breast cancer risk: a meta-analysis.Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?The role of NSAIDs in the prevention of colon cancer.Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.Sulindac inhibits neointimal formation after arterial injury in wild-type and apolipoprotein E-deficient mice.Chemoprevention in gastrointestinal physiology and disease. Anti-inflammatory approaches for colorectal cancer chemopreventionWnt signalling and prostate cancer.The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.NSAIDs and Colorectal Cancer Control: Promise and ChallengesCyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studiesPhosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenograftsDevelopment of novel agents based on nitric oxide for the control of colon cancer.Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized studyThe NOD-like receptor NLRP12 attenuates colon inflammation and tumorigenesis.Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53-dependent G1 cell cycle arrest and autophagy.New NSAID targets and derivatives for colorectal cancer chemoprevention.
P2860
Q24792522-19B0C281-9D06-4AC9-B8DE-11948CA52CD6Q24801805-CB660691-F821-4753-85A1-50CE0E864123Q24803838-CE9AC10A-9ECC-4460-B9D4-9332BA439422Q24814415-3E8FB77B-CAD6-4F5D-BD9F-52C2B6F2D6A9Q26774588-637560AB-EA62-4D41-94D4-B3408766BDFFQ27664075-7B1CEDB3-D44F-45DC-91A7-8139EC3AE0A7Q28087427-A206ED61-8782-4C48-AD96-E63FB71E0F31Q28165527-9C1D5609-6782-402F-8BD8-1FE423036189Q28165770-96523636-F8DA-4B18-AF6E-C0E2389E4D1BQ28166679-137C20A8-B24A-4C3A-99C5-C6CE0C19DB9EQ28183525-A89FF7B0-C7A9-4BED-BAD8-F6DDD0C5E258Q28191533-8FC50981-A112-4543-944A-50BD736AF18FQ28217572-CCF3BB16-9AFD-4938-B4F6-DA130A6DE975Q30367680-9A76DE9E-8BA8-42BB-9465-C8B08C4ABBC4Q31919547-BC73634C-ACC3-49C2-AC76-A97373F983D5Q33619700-DFC1CC07-E674-42A8-990F-8E54EC90412DQ33640592-B4340E77-491F-41B2-8F58-CCA68EDB4471Q33748296-C9D86EE2-0D5A-4214-A70E-8B89C6A519AEQ33798506-E1EFB2F4-B9AB-49B1-A48C-BD91F6EF22F2Q33834689-67C11818-0C63-4056-88F9-CA99681608D3Q34069337-1034DA92-6601-44C7-8397-BABA421C99E7Q34253357-CF6A4F91-1C26-4690-84F6-FAAED24E3FD3Q34378429-2328F29D-8087-4499-AC74-EAD41C8BBE3AQ34458235-1CE4D1B1-835F-4048-90D4-0F759AE4FBF1Q34966050-810DBA6B-82E6-4DD0-8270-B493074B4852Q35008304-DE9461E8-13CE-4676-8FB2-8CB9A9CC5449Q35091403-0D81E6B1-E8B1-41F3-AFE5-5C921BBF1FE7Q35824529-5710AA99-49D9-48C2-9CED-D970C3EEAB94Q35859243-9DAF0414-88EC-4826-89F5-583E15CBE108Q36089054-117973F5-D72E-430C-A65D-F375EC1CCF2AQ36147300-C1639D22-951B-4C70-8622-E32FBB1B883CQ36381490-AB3CFBBE-AA4D-41E7-A8E5-62976BB11B33Q36498885-229447D8-878D-45E0-8650-4B3158B1FFB9Q36740696-858C49FA-A8C6-4516-B135-779A81F76CF5Q36752069-669AFFEA-8F15-42F4-A996-AADCAC8BEF50Q36920783-4CBB96CF-58F6-4225-B48C-63CA4647A030Q37101384-B00D0175-DAFB-40F7-B57C-0C03A4605708Q37144338-37A8E64B-7067-4BC5-9EA8-01A2BC2E356DQ37341268-EC1C77EF-6810-403D-BB35-C6C29B07D143Q38034670-89E5A35B-5A0A-4561-B2E1-B057AE6B6E0B
P2860
The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)
description
1999 nĆ® lÅ«n-bĆ»n
@nan
1999幓ć®č«ę
@ja
1999幓å¦ęÆęē«
@wuu
1999幓å¦ęÆęē«
@zh-cn
1999幓å¦ęÆęē«
@zh-hans
1999幓å¦ęÆęē«
@zh-my
1999幓å¦ęÆęē«
@zh-sg
1999幓åøč”ęē«
@yue
1999幓åøč”ęē«
@zh
1999幓åøč”ęē«
@zh-hant
name
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@ast
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@en
type
label
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@ast
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@en
prefLabel
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@ast
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@en
P2860
P356
P1476
The role of cyclooxygenase inh ...... ntiinflammatory drugs (NSAIDs)
@en
P2093
P2860
P304
P356
10.1084/JEM.190.4.445
P407
P577
1999-08-01T00:00:00Z